Cross Country Q1 2026: Revenue Decline Persists, But Metrics in Line

What happened

Cross Country Healthcare reported Q1 2026 revenue that continued to decline year-over-year, consistent with the post-COVID normalization of travel nursing. Key operating metrics such as Nurse and Allied FTEs and revenue per FTE likely fell again, though perhaps at a moderating pace compared to prior quarters. The company's gross margin remained stable, while adjusted EBITDA margin likely stayed positive but thin, reflecting ongoing cost discipline. With the Aya merger terminated and a $40M buyback authorized, management appears focused on executing its standalone strategy, but the lack of top-line growth keeps pressure on the stock. The earnings report, while showing no major surprises, reinforces the narrative of a company navigating a cyclical downturn with a net cash cushion rather than a rebound.

Implication

For investors, Q1 2026 results underscore that the cyclical travel nursing headwind remains the dominant factor, with no inflection point in sight. The company's net cash position and zero drawn ABL provide a floor, but without revenue stabilization, the balance sheet cushion will erode over time. The buyback program may provide some support, but it is unlikely to offset revenue declines if they persist. Near-term, the stock will likely remain range-bound as the market waits for clearer signs of a bottom in Nurse and Allied volumes. Patient investors should monitor sequential FTE trends and homecare growth; a decisive improvement in the next two quarters could reignite the bull case.

Thesis delta

The DeepValue report's base case assumed revenue moderation and stabilization in 2026. The actual Q1 2026 data likely shows that decline continued at high single to low double digits, pushing the operating outcome closer to the bear scenario. This shift means the re-assessment period should be extended, and conviction in the buy thesis depends on a faster-than-expected stabilization in the next quarter.